Neurocrine Biosciences ‘ drug pipeline is turning a corner and the company will be “knocking on the doors of the large-cap club” soon, according to Wells Fargo. Analyst Mohit Bansal upgraded shares to overweight from equal weight, and raised his price target to $170 from $140, suggesting around 21% upside potential from Tuesday’s close. Bansal forecasts the company’s congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. “Crinecerfont alone is enough to make for a buy case,” Bansal wrote in a Tuesday note. “We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity.” Elsewhere in the company’s pipeline, Neurocrine’s depression drug NBI-1065845, developed in conjunction with Japanese pharmaceutical company Takeda, showed positive results during a phase II trial. Bansal said this drug could open “a whole new chapter” of a $1.2 billion peak sales opportunity. The NBI-‘845 treatment could be “another blockbuster opportunity,” Bansal said, citing the treatment’s once-daily administration as a factor in his assessment. Competing therapies are taken twice a day, he said. Shares are up nearly 6% in 2024. The stock has rallied about 35% over the past 12 months. — CNBC’s Michael Bloom contributed to this report.
FOLLOW US ON GOOGLE NEWS
Read original article here
Denial of responsibility! Chronicles Live is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email –
chronicleslive.com. The content will be deleted within 24 hours.
